Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study

Durand CM, Barnaba B, Yu S, et al. Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study. Ann Intern Med. 2021;174(1):137-138.

Publication Type:

Journal Article

Authors:

Durand, CM; Barnaba, B; Yu, S; et, al

Source:

Ann Intern Med, Volume 174, Issue 1, p.137-138 (2021)

Cited On:

Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors

Export Citation:

RIS Format

Top